SAN FRANCISCO, Jan. 2, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, today
announced that Matthew R. Patterson,
Chairman and Chief Executive Officer, will provide a corporate
overview and 2019 outlook at the 37th Annual J.P. Morgan
Healthcare Conference in San
Francisco, CA. The presentation is scheduled for
Tuesday, January 8, 2019, at
3:30 pm PST.
To access a live webcast of the presentations, please visit the
Events & Presentations page within the Investors & News
section of the Audentes website. Replays of live webcasts
will be available on the Audentes website for approximately 30 days
following the conferences.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on
developing and commercializing innovative gene therapy products for
patients living with serious, life-threatening rare diseases.
We are currently conducting Phase 1/2 clinical studies of our lead
product candidates, AT132 for the treatment of X-linked Myotubular
Myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar
syndrome. We have two additional product candidates in
development, including AT982 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
catecholaminergic polymorphic ventricular tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-300770517.html
SOURCE Audentes Therapeutics, Inc.